BACKGROUND: The emergence of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in early 2020 and subsequent implementation of public health and social measures (PHSM) disrupted the epidemiology of respiratory viruses. This work describes the epidemiology of respiratory syncytial virus (RSV) observed during two winter seasons (weeks 40-20) and inter-seasonal periods (weeks 21-39) during the pandemic between October 2020 and September 2022. METHODS: Using data submitted to The European Surveillance System (TESSy) by countries or territories in the World Health Organization (WHO) European Region between weeks 40/2020 and 39/2022, we aggregated country-specific weekly RSV counts of sentinel, non-sentinel and Severe Acute Respiratory Infection (SARI) surveillance specimens and calculated percentage positivity. Results for both 2020/21 and 2021/22 seasons and inter-seasons were compared with pre-pandemic 2016/17 to 2019/20 seasons and inter-seasons. RESULTS: Although more specimens were tested than in pre-COVID-19 pandemic seasons, very few RSV detections were reported during the 2020/21 season in all surveillance systems. During the 2021 inter-season, a gradual increase in detections was observed in all systems. In 2021/22, all systems saw early peaks of RSV infection, and during the 2022 inter-seasonal period, patterns of detections were closer to those seen before the COVID-19 pandemic. CONCLUSION: RSV surveillance continued throughout the COVID-19 pandemic, with an initial reduction in transmission, followed by very high and out-of-season RSV circulation (summer 2021) and then an early start of the 2021/22 season. As of the 2022/23 season, RSV circulation had not yet normalised.
x
- MeSH
- antigeny CD273 antagonisté a inhibitory MeSH
- cílená molekulární terapie metody MeSH
- imidazoly škodlivé účinky terapeutické užití MeSH
- imunoterapie metody MeSH
- indoly škodlivé účinky terapeutické užití MeSH
- inhibitory proteinkinas škodlivé účinky terapeutické užití MeSH
- kombinovaná farmakoterapie škodlivé účinky MeSH
- lidé MeSH
- melanom * farmakoterapie genetika MeSH
- monoklonální protilátky terapeutické užití MeSH
- mutace účinky léků MeSH
- nádory kůže chemicky indukované MeSH
- oximy škodlivé účinky terapeutické užití MeSH
- protoonkogenní proteiny B-raf * antagonisté a inhibitory genetika MeSH
- spinocelulární karcinom chemicky indukované MeSH
- sulfonamidy škodlivé účinky terapeutické užití MeSH
- Check Tag
- lidé MeSH
